On the stock market since 2021, it operates in the world of health and science. It has 163 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $302.4M in the vault; even if every debt were paid off, $298.0M would remain.
It met or beat analyst expectations in 6 of the last 7 quarters — consistency is a promise kept.
It pays out $9.55 per share each year — regular cash for whoever holds the stock.
A loss of $110.3M against $0 in annual sales.
The stock sits at $0.32. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, LIAN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LIAN is a high-risk stock — not yet profitable, and its future rides on its product catching on.